Immunicum - ilixadencel in MERECA Phase II - results soon ! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunicum - ilixadencel in MERECA Phase II - results soon !

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: loparn	12/20/2019 3:55:29 AM
	of 17

"Immunicum AB (publ; IMMU.ST) announced today that the abstract covering data from the Phase II MERECA trial has been accepted for an oral presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium, which will be held February 6-8, 2020 in Orlando, Florida. The MERECA trial investigated the therapeutic benefit of combining Immunicum’s lead product, ilixadencel, and Sutent® (sunitinib) as a first-line treatment in patients with metastatic kidney cancer. Immunicum announced top-line results from the study in the third quarter of 2019 and will present more detailed results at the symposium, including the first half-yearly follow-up of patient survival in the study." immunicum.se

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next